Budigalimab
- Generic Name
- Budigalimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2098225-93-3
- Unique Ingredient Identifier
- 6VDO4TY3OO
- Background
Budigalimab is under investigation in clinical trial NCT04807972 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 Is Administered in Combination With IV Modified FOLFIRINOX (Mffx) With or Without IV Budigalimab Compared to Mffx in Adult Participants With Untreated Pancreatic Cancer Metastasis).
- Associated Conditions
- -
- Associated Therapies
- -
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
- Conditions
- Interventions
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 150
- Registration Number
- NCT06632951
- Locations
- 🇺🇸
Highlands Oncology Group - Springdale /ID# 270290, Springdale, Arkansas, United States
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
- First Posted Date
- 2024-10-04
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 180
- Registration Number
- NCT06628310
- Locations
- 🇺🇸
City of Hope National Medical Center /ID# 268690, Duarte, California, United States
🇺🇸Hattiesburg Clinic /ID# 268572, Hattiesburg, Mississippi, United States
🇺🇸Millennium Research & Clinical Development /ID# 268540, Houston, Texas, United States
A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)
- Conditions
- Interventions
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 20
- Registration Number
- NCT06487559
- Locations
- 🇨🇳
Hubei Cancer Hospital /ID# 262030, Wuhan, Hubei, China
🇨🇳Zhejiang Cancer hospital /ID# 262046, Hangzhou, Zhejiang, China
🇨🇳Mengchao Hepatobiliary Hospital of Fujian Medical University /ID# 262443, Fuzhou, Fujian, China
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 840
- Registration Number
- NCT06236438
- Locations
- 🇺🇸
University of Kansas Medical Center /ID# 263196, Westwood, Kansas, United States
🇺🇸Memorial Hospital West /ID# 262221, Pembroke Pines, Florida, United States
🇺🇸Bond Clinic /ID# 262611, Winter Haven, Florida, United States
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 192
- Registration Number
- NCT06158958
- Locations
- 🇺🇸
NYU Langone - Laura and Isaac Perlmutter Cancer Center /ID# 256943, New York, New York, United States
🇺🇸City of Hope /ID# 254303, Duarte, California, United States
🇺🇸City of Hope at Orange County Lennar Foundation Cancer Center /ID# 266792, Irvine, California, United States
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
- Conditions
- Interventions
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 660
- Registration Number
- NCT06109272
- Locations
- 🇮🇹
Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 265506, Rome, Roma, Italy
🇺🇸City of Hope /ID# 261468, Duarte, California, United States
🇺🇸City of Hope at Orange County Lennar Foundation Cancer Center /ID# 261669, Irvine, California, United States
A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382
- Conditions
- Interventions
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 140
- Registration Number
- NCT06032546
- Locations
- 🇵🇷
Clinical Research Puerto Rico /ID# 256956, San Juan, Puerto Rico
🇵🇷HOPE Clinical Research /ID# 257487, San Juan, Puerto Rico
🇿🇦Wits RHI Research Centre /ID# 257354, Johannesburg, Gauteng, South Africa
Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
- Conditions
- Interventions
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 120
- Registration Number
- NCT05822752
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers - Denver Midtwon /ID# 254163, Denver, Colorado, United States
🇮🇹IRCCS AOU di Bologna - Policlinico Sant'Orsola-Malpighi /ID# 253247, Bologna, Emilia-Romagna, Italy
🇺🇸Arizona Oncology Associates, PC - NAHOA Prescott Valley /ID# 254313, Prescott Valley, Arizona, United States
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 350
- Registration Number
- NCT05599984
- Locations
- 🇩🇪
Klinikum der Universität München - Campus Innenstadt /ID# 259412, Munich, Bayern, Germany
🇺🇸Banner MD Anderson Cancer Ctr /ID# 260129, Gilbert, Arizona, United States
🇺🇸City Of Hope Comprehensive Cancer Center /ID# 271295, Duarte, California, United States
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Budigalimab
- Conditions
- Interventions
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 268
- Registration Number
- NCT05005403
- Locations
- 🇺🇸
University of Illinois at Chicago /ID# 251750, Chicago, Illinois, United States
🇺🇸Fort Wayne Medical Oncology and Hematology, Inc /ID# 232593, Fort Wayne, Indiana, United States
🇺🇸Community Health Network, Inc. /ID# 243011, Indianapolis, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.